CURRENT SURGICAL RISK SCORES OVERESTIMATE THE RISK ASSOCIATED WITH MINIMALLY INVASIVE AORTIC VALVE REPLACEMENT IN LOW-RISK PATIENTS

2019 ◽  
Vol 73 (9) ◽  
pp. 1967
Author(s):  
Ahmed Alnajar ◽  
Subhasis Chatterjee ◽  
Brenden Chou ◽  
Mariam Khabsa ◽  
Madeline Rippstein ◽  
...  
Author(s):  
Ahmed Alnajar ◽  
Subhasis Chatterjee ◽  
Brendan P. Chou ◽  
Mariam Khabsa ◽  
Madeline Rippstein ◽  
...  

Objective Risk-scoring systems for surgical aortic valve replacement (AVR) were largely derived from sternotomy cases. We evaluated the accuracy of current risk scores in predicting outcomes after minimally invasive AVR (mini-AVR). Because transcatheter AVR (TAVR) is being considered for use in low-risk patients with aortic stenosis, accurate mini-AVR risk assessment is necessary. Methods We reviewed 1,018 consecutive isolated mini-AVR cases (2009 to 2015). After excluding patients with Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) scores ≥4, we calculated each patient’s European System for Cardiac Operative Risk Evaluation (EuroSCORE) II, TAVR Risk Score (TAVR-RS), and age, creatinine, and ejection fraction score (ACEF). We compared all 4 scores’ accuracy in predicting mini-AVR 30-day mortality by computing each score’s observed-to-expected mortality ratio (O:E). Area under the receiver operating characteristic (ROC) curves tested discrimination, and the Hosmer–Lemeshow goodness-of-fit tested calibration. Results Among 941 patients (mean age, 72 ± 12 years), 6 deaths occurred within 30 days (actual mortality rate, 0.6%). All 4 scoring systems overpredicted expected mortality after mini-AVR: ACEF (1.4%), EuroSCORE II (1.9%), STS-PROM (2.0%), and TAVR-RS (2.1%). STS-PROM best estimated risk for patients with STS-PROM scores 0 to <1 (0.6 O:E), ACEF for patients with STS-PROM scores 2 to <3 (0.6 O:E), and TAVR-RS for patients with STS-PROM scores 3 to <4 (0.7 O:E). ROC curves showed only fair discrimination and calibration across all risk scores. Conclusions In low-risk patients who underwent mini-AVR, current surgical scoring systems overpredicted mortality 2-to-3-fold. Alternative dedicated scoring systems for mini-AVR are needed for more accurate outcomes assessment.


2019 ◽  
Vol 56 (5) ◽  
pp. 1016-1017
Author(s):  
Marco Di Eusanio ◽  
Mariano Cefarelli ◽  
Paolo Berretta ◽  
Filippo Capestro

Abstract Patients with severe aortic valve stenosis are currently treated with 2 different interventional techniques: surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI). Both have strengths and limitations. On the one hand, TAVI represents a valuable option in high- and intermediate-risk patients and is commonly preferred over surgical aortic valve replacement in subjects with porcelain or severely calcified aorta, on the other, the lack of data on valve durability raises concerns on its use in young, low-risk patients. We present herein the case of a low-risk 71-year-old patient with a severely calcified ascending aorta. We successfully combined our minimally invasive surgical approach with the use of a percutaneous cerebral protection system commonly employed during TAVI procedures. We believe that cardiac surgeons could adopt transcatheter technology to improve operative results.


Author(s):  
Mark J. Russo ◽  
Vinod H. Thourani ◽  
David J. Cohen ◽  
S. Chris Malaisrie ◽  
Wilson Y. Szeto ◽  
...  

2020 ◽  
Vol 7 ◽  
Author(s):  
Pier Paolo Bocchino ◽  
Filippo Angelini ◽  
Brunilda Alushi ◽  
Federico Conrotto ◽  
Giacomo Maria Cioffi ◽  
...  

In the last decades, transcatheter aortic valve replacement (TAVR) revolutionized the treatment of symptomatic severe aortic stenosis. The efficacy and safety of TAVR were first proven in inoperable and high-risk patients. Then, subsequent randomized clinical trials showed non-inferiority of TAVR as compared to surgical aortic valve replacement also in intermediate- and low-risk populations. As TAVR was progressively studied and clinically used in lower-risk patients, issues were raised questioning its opportunity in a younger population with a longer life-expectancy. As long-term follow-up data mainly derive from old studies with early generation devices on high or intermediate surgical risk patients, results can hardly be extended to most of currently treated patients who often show a low surgical risk and are treated with newer generation prostheses. Thus, in this low-risk younger population, decision making is difficult due to the lack of supporting data. The aim of the present review is to revise current literature regarding TAVR in younger patients.


Sign in / Sign up

Export Citation Format

Share Document